You may have seen recent news about advances in early cancer detection. We're excited to share that we now offer a revolutionary multi-cancer early detection test for our patients.
It’s called the Galleri Multi-Cancer Early-Detection Test* and it can detect more than 50 types of cancer by looking for signals in the blood that may be associated with cancer.1,2 If caught in its early stages, cancer treatment outcomes and survival rates may be improved.
Here are few benefits of the test:
It detects many cancers that are not commonly screened for today, so you can get treated earlier.
It can be incorporated into a routine visit through a simple blood draw.
If a cancer signal is found, the results point to where in the body the cancer is coming from to help us guide your next steps.
You can learn more about the test by watching a short explainer video below.
Visit to review Important Safety Information
*The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged
50 or older. It is intended to be used in addition to, and not replace, other cancer screening tests.
1. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Abstract
LB013. Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting April 10 – 15, 2021.
2. Amin MB, et al. (Eds). American Joint Committee of Cancer (AJCC) Cancer Staging Manual (8th edition)
3. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs
Research Data, Nov 2018 Sub. Includes persons aged 50-79 diagnosed 2006-2015 “Early/Localized” includes invasive localized tumors
that have not spread beyond organ of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ
of origin to other parts of the body
